These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 20016304)

  • 21. Spironolactone in the treatment of hypertension: a review.
    Brest AN
    Clin Ther; 1986; 8(5):568-85. PubMed ID: 2876776
    [No Abstract]   [Full Text] [Related]  

  • 22. [Antikaliuretic agents].
    Esch I
    Internist (Berl); 1971 Aug; 12():Suppl:352-6. PubMed ID: 4937775
    [No Abstract]   [Full Text] [Related]  

  • 23. Spironolactone and chlorthalidone in uncontrolled elderly hypertensive patients treated with calcium antagonists and angiotensin II receptor-blocker: effects on endothelial function, inflammation, and oxidative stress.
    Yamanari H; Nakamura K; Miura D; Yamanari S; Ohe T
    Clin Exp Hypertens; 2009 Oct; 31(7):585-94. PubMed ID: 19886856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Use of spironolactone and indapamide in the treatment of low-renin arterial hypertension].
    Naudzhunas A; Bagdonas G; Yankauskene L; Kazanavichus G
    Ter Arkh; 2006; 78(2):61-4. PubMed ID: 16613101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Correlations between blood pressure, blood volume and plasma renin during therapy with diuretics in essential hypertension. Comparison between the mineralocorticoid antagonist spironolactone and the "loop" diuretic mefruside].
    Beretta-Piccoli C; Weidmann P; de Châtel R; Hirsch D; Reubi FC
    Schweiz Med Wochenschr; 1977 Jan; 107(4):104-15. PubMed ID: 834983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Spironolactone-induced changes of the renin-angiotensin-aldosterone system and blood pressure lowering in essential hypertension].
    Furrer J; Vetter W; Nussberger J; Beckerhoff R; Siegenthaler W
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():235-6. PubMed ID: 349929
    [No Abstract]   [Full Text] [Related]  

  • 27. Estimation of plasma potassium, renin and aldosterone in the diagnosis of primary hyperaldosteronism; the role of spironolactone in the treatment of this syndrome.
    Brown JJ; Chinn RH; Dusterdieck G; Fraser R; Lever AF; Robertson JI; Tree M
    J Endocrinol; 1969 Jan; 43(1):iv-v. PubMed ID: 5773780
    [No Abstract]   [Full Text] [Related]  

  • 28. Hyperaldosteronism: recent concepts, diagnosis, and management.
    Foo R; O'Shaughnessy KM; Brown MJ
    Postgrad Med J; 2001 Oct; 77(912):639-44. PubMed ID: 11571370
    [No Abstract]   [Full Text] [Related]  

  • 29. [Role of antialdosteronics in the treatment of refractory hypertension].
    Roca-Cusachs Coll A
    Med Clin (Barc); 2008 Oct; 131(11):416-8. PubMed ID: 18928722
    [No Abstract]   [Full Text] [Related]  

  • 30. [Treatment of secondary hyperaldosteronism].
    Werning C; Siegenthaler W
    Dtsch Med Wochenschr; 1969 Oct; 94(40):2051-3. PubMed ID: 5356332
    [No Abstract]   [Full Text] [Related]  

  • 31. Response of blood pressure and the renin-angiotensin-aldosterone axis to hypotensive therapy: comparison of propranolol with spironolactone.
    Espiner EA; Mansfield H; Miles K
    N Z Med J; 1977 Sep; 86(595):216-9. PubMed ID: 343004
    [No Abstract]   [Full Text] [Related]  

  • 32. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG; Schencking M; Scheer C; Rupp H
    Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The effect of aldosterone antagonists in juvenile heart surgery].
    Wimmer M; Parth K; Holzer H
    Acta Med Austriaca; 1979; 6(1):8-12. PubMed ID: 506658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical study of verospirone and spironolactone.
    Gãbor G; Bekes M; Polãk G; Rausch J; Gulyãs A
    Ther Hung; 1972; 20(1):36-45. PubMed ID: 5076528
    [No Abstract]   [Full Text] [Related]  

  • 35. Spironolactone for heart failure.
    Med Lett Drugs Ther; 1999 Sep; 41(1061):81-2. PubMed ID: 10505071
    [No Abstract]   [Full Text] [Related]  

  • 36. Primary hyperaldosteronism in a patient with end-stage renal disease.
    Kazory A; Weiner ID
    Nephrol Dial Transplant; 2007 Mar; 22(3):917-9. PubMed ID: 17127694
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment of essential arterial hypertension with spironolactone: its value in the detection of primary hyperaldosteronism and prediction of its efficacy].
    Fournier A; Nakache JP; Salmon D; Kazandjian M; Baulon A; Legrand JC; Menard J; Lagrue G
    J Urol Nephrol (Paris); 1972 Dec; 78(12):1023-7. PubMed ID: 4661188
    [No Abstract]   [Full Text] [Related]  

  • 38. [New clinical application of spironolactone].
    Fukuchi S
    Nihon Rinsho; 1974 Nov; 32(11):3326-32. PubMed ID: 4615183
    [No Abstract]   [Full Text] [Related]  

  • 39. Management of primary and secondary hyperaldosteronism.
    Br Med J; 1969 Aug; 3(5668):427-8. PubMed ID: 5811648
    [No Abstract]   [Full Text] [Related]  

  • 40. Verapamil and nifedipine in combination for the treatment of hypertrophy heart disease.
    Kaesemeyer WH; Prisant LM; Carr AA
    Am J Hypertens; 1991 Oct; 4(10 Pt 1):866-7. PubMed ID: 1747220
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.